CureVac (CVAC) Competitors

Cytokinetics (NASDAQ:CYTK) and CureVac (NASDAQ:CVAC) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, analyst recommendations, community ranking, institutional ownership, earnings, valuation, dividends, profitability and media sentiment.

Does the MarketBeat Community prefer CYTK or CVAC?

Cytokinetics received 803 more outperform votes than CureVac when rated by MarketBeat users. Likewise, 79.83% of users gave Cytokinetics an outperform vote while only 57.14% of users gave CureVac an outperform vote.

Company	Underperform	Outperform
Cytokinetics	Outperform Votes 831 79.83%	Underperform Votes 210 20.17%
CureVac	Outperform Votes 28 57.14%	Underperform Votes 21 42.86%

Do analysts recommend CYTK or CVAC?

Cytokinetics currently has a consensus target price of $70.92, suggesting a potential upside of 113.62%. CureVac has a consensus target price of $11.00, suggesting a potential upside of 96.43%. Given Cytokinetics' higher possible upside, research analysts clearly believe Cytokinetics is more favorable than CureVac.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cytokinetics	0 Sell rating(s)	3 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	2.93
CureVac	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00

Does the media refer more to CYTK or CVAC?

In the previous week, CureVac had 1 more articles in the media than Cytokinetics. MarketBeat recorded 18 mentions for CureVac and 17 mentions for Cytokinetics. CureVac's average media sentiment score of 1.20 beat Cytokinetics' score of 0.35 indicating that CureVac is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cytokinetics	6 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Neutral
CureVac	7 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive

Which has more volatility & risk, CYTK or CVAC?

Cytokinetics has a beta of 0.59, indicating that its stock price is 41% less volatile than the S&P 500. Comparatively, CureVac has a beta of 2.49, indicating that its stock price is 149% more volatile than the S&P 500.

Do institutionals and insiders believe in CYTK or CVAC?

17.3% of CureVac shares are held by institutional investors. 2.7% of Cytokinetics shares are held by company insiders. Comparatively, 2.2% of CureVac shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Is CYTK or CVAC more profitable?

CureVac has a net margin of 20.72% compared to Cytokinetics' net margin of -17,906.25%. CureVac's return on equity of 21.98% beat Cytokinetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cytokinetics	-17,906.25%	N/A	-50.21%
CureVac	20.72%	21.98%	15.72%

Which has better valuation & earnings, CYTK or CVAC?

CureVac has higher revenue and earnings than Cytokinetics. Cytokinetics is trading at a lower price-to-earnings ratio than CureVac, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cytokinetics	$19.22M	206.32	-$526.24M	-$5.29	-6.28
CureVac	$523.70M	2.40	-$281.58M	$0.92	6.09

Summary

CureVac beats Cytokinetics on 12 of the 19 factors compared between the two stocks.